Guo-Wen Wang

Tianjin Medical University Cancer Institute and Hospital, T’ien-ching-shih, Tianjin Shi, China

Are you Guo-Wen Wang?

Claim your profile

Publications (3)1.48 Total impact

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Melanoma is an intractable cancer that is aggressive, lethal, and metastatic. The prognosis of advanced melanoma is very poor because it is insensitive to chemotherapy and radiotherapy. The incidence of melanoma has been ascending stably for years worldwide, accompanied by increasing mortality. New approaches to managing this deadly disease are much anticipated to enhance the cure rate and to extend clinical benefits to patients with metastatic melanoma. Due to its high degree of immunogenicity, melanoma could be a good target for immunotherapy, which has been developed for decades and has achieved certain progress. This article provides an overview of immunotherapy for melanoma.
    Ai zheng = Aizheng = Chinese journal of cancer 09/2014; 33(9):458-65. DOI:10.5732/cjc.014.10118
  • Source
    Lin-Ru Zhao · Wei Tian · Guo-Wen Wang · Ke-Xin Chen · Ji-Long Yang
    [Show abstract] [Hide abstract]
    ABSTRACT: PRUNE2 has played an important role in regulating tumor cell differentiation, proliferation and invasiveness in neuroblastoma. Our previous study revealed that the PRUNE2/OBSCN relative expression could distinguish between gastrointestinal stromal tumor and leiomyosarcoma accurately. However, the correlation between PRUNE2 expression and prognosis was poorly understood in leiomyosarcoma patients. In this study, we aim to evaluate the prognostic role of PRUNE2 in leiomyosarcoma. The PRUNE2 protein expression was detected by immunohistochemistry (IHC) in 30 formalin-fixed and paraffin-embedded (FFPE) leiomyosarcoma tissues from MD Anderson Cancer Center (MDACC) and the high expression of PRUNE2 was 36.7% (11/30). To validate the results, another cohort of 45 FFPE leiomyosarcoma tissues from Tianjin Medical University Cancer Institute & Hospital (TMUCIH) was collected and PRUNE2 protein expression was detected by IHC. The results showed that the high expression rate of PRUNE2 protein in TMUCIH samples was 37.8% (17/45) and the elevated PRUNE2 expression was significantly associated with tumor size (P=0.03). Not only the high expression level of PRUNE2 protein was a significant favorable prognostic factor for overall survival in TMUCIH leiomyosarcoma patients (P<0.05), multivariate analysis revealed that the protein expression of PRUNE2 was also an independent prognostic factor. These data suggest that increased PRUNE2 protein expression may serve as a favorable prognostic marker in human leiomyosarcoma.
    Ai zheng = Aizheng = Chinese journal of cancer 06/2013; 32(12). DOI:10.5732/cjc.013.10069
  • Jian Duo · Guo-Guang Ying · Guo-Wen Wang · Li Zhang
    [Show abstract] [Hide abstract]
    ABSTRACT: Breast cancer is a disease in which cancer cells form in the tissues of the breast. The present study aimed to explore the effect of the flavonoid compound quercetin on the growth and apoptosis of human breast cancer cells. Varying concentrations (12.5, 25, 50, 100, 200 µM) of quercetin were applied to cultured MCF-7 human breast cancer cells for defined lengths of time. At 50 to 200 µM doses, quercetin significantly inhibited the proliferation of MCF-7 cells assessed by MTT colorimetry, in both dose- and time-dependent manners (P<0.05). The compound also increased apoptosis after 48 h of exposure (P<0.05). Furthermore, following quercetin treatment Bcl-2 expression decreased significantly while Bax expression increased significantly (P<0.05). In brief, quercetin inhibits cell growth and induces apoptosis in MCF-7 human breast cancer cells. The mechanisms behind these effects may stem from the downregulation of Bcl-2 protein expression and upregulation of Bax expression.
    Molecular Medicine Reports 03/2012; 5(6):1453-6. DOI:10.3892/mmr.2012.845 · 1.48 Impact Factor

Publication Stats

27 Citations
1.48 Total Impact Points


  • 2012–2013
    • Tianjin Medical University Cancer Institute and Hospital
      T’ien-ching-shih, Tianjin Shi, China